Tag: Revance

All

Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox

Will Revance's RT001 be the first topically neurotoxin treatment?

All

Studies Show Efficacy of Daxxify to Treat Frown Lines

Revance announced that two studies showed Daxxify was an effective and safe treatment for frown lines and improvements to eyebrow position.

AbbVie’s Botox Patent Lawsuit is ‘Very Unlikely to Derail’ Revance’s Rival Launch: Analysts
Revance Presents DaxibotulinumtoxinA for Injection and RHA Collection Data at the ASDS Virtual Annual Meeting
Revance Plans to Introduce Its Aesthetic Portfolio in September
Studies of DaxibotulinumtoxinA Injection to Treat Forehead Lines and Crow’s Feet Produce Positive Results, Revance Announces
Revance and Mylan to Advance Development Program for Biosimilar to BOTOX
Revance Therapeutics Inc Announces Study Results and a License Agreement for RT002

All

Labiaplasty Surgeries on the Rise

Here, Alexis Parcells, MD, FACS, a board-certified plastic surgeon and owner of Eatontown, N.J.-based Parcells Plastic Surgery, discusses what’s behind the surge of labiaplasty surgeries.

Hot Stuff: November 2015

by Debbie Overman | Oct 28, 2015 | Sculpting | 0

JUVEDERM ULTRA XC for lips and Coolscupting’s new Coolmini for the double chin are among November’s “Hot Stuff.”

Tag: Revance

All

Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox

Cosmetic Surgery Foundation Welcomes New Members to Industry Advisory Council

The Face: It’s Faux Tox Time

Revance Relocates from California to Tennessee

Long Shot: Revance’s RT002 May Banish Frown Lines for 7 Months

Aji Bio-Pharma and Revance in Manufacturing Deal for Anti-Wrinkle Rival to Botox

Hot Stuff: February 2015

Revance Therapeutics Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection

As Revance Nears a Potential Launch for its Botox Rival, AbbVie Sues for Patent Infringement

All

Studies Show Efficacy of Daxxify to Treat Frown Lines

AbbVie’s Botox Patent Lawsuit is ‘Very Unlikely to Derail’ Revance’s Rival Launch: Analysts

Revance Presents DaxibotulinumtoxinA for Injection and RHA Collection Data at the ASDS Virtual Annual Meeting

Revance Plans to Introduce Its Aesthetic Portfolio in September

Studies of DaxibotulinumtoxinA Injection to Treat Forehead Lines and Crow’s Feet Produce Positive Results, Revance Announces

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX

Revance Therapeutics Inc Announces Study Results and a License Agreement for RT002

All

Labiaplasty Surgeries on the Rise

Shroom Skincare Unveils Mushroom-Based Serum

ABFCS Elects New Officers and Trustees for 2023

AI Interpretations of Pain Drawings May Predict Response to Headache Surgery

Hot Stuff: November 2015